Abstract
As personalized medicine continues to evolve, the formulations required must be able to adequately meet the needs of a relatively small and diverse patient population from the earliest phases of new drug development, while at the same time being low cost. Personalized formulations for use by children and the elderly often rely on clinical site compounding. From the time a new drug product is designed, formulations should be universally designed to be crushed, suspended, and administered by tube. Orally disintegrating tablets have characteristics similar to those of universal design, but they interact with thickened water, which is used by the elderly who have difficulty swallowing to take their medication, and children should be cautious because they do not like orally flavored formulations. In contrast, clinical trials have shown that mini tablets can be taken even by infants, and therefore, the mini tablets are considered promising as a pediatric formulation in the future.
